Literature DB >> 23397083

Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs.

Q Quentin Li1, Gangduo Wang, Furong Huang, Jueli M Li, Christopher F Cuff, Eddie Reed.   

Abstract

The development of effective agents for overcoming platinum chemoresistance in lung carcinoma continues to have high priority. We have demonstrated recently that β-elemene, a novel antitumor compound, enhances cisplatin activity by triggering lung cancer cell death via apoptosis. Here, we investigated whether β-elemene acts synergistically with cisplatin to inhibit non-small cell lung cancer (NSCLC) cell proliferation by blocking cell cycle progression. β-Elemene substantially increased the suppressive effect of cisplatin on cell growth and proliferation in the NSCLC cell lines H460 and A549. Furthermore, β-elemene augmented cisplatin in the cell cycle arrest of NSCLC cells at G(2)/M. This was associated with upregulated checkpoint kinase (CHK2) expression and reduced CDC2 activity (i.e., increased phosphorylation of CDC2 on Tyr-15 and decreased phosphorylation of CDC2 on Thr-161). Moreover, β-elemene and cisplatin in combination clearly decreased the protein levels of cyclin B1 and CDC25C and increased the levels of p21(Cip1/Waf1), p27(Kip1), and GADD45 in these cells, compared with the effects of either agent alone at the same concentration. These results suggest that the β-elemene-enhanced inhibitory effect of cisplatin on lung carcinoma cell proliferation is regulated by a CHK2-mediated CDC25C/CDC2/cyclin B1 signaling pathway and leads to the blockade of cell cycle progression at G(2)/M. A comparison of the cytotoxic efficacies of β-elemene and three synthetic analogs (β-elemenol, β-elemenal, and β-elemene fluoride) in the two lung cancer cell lines revealed that β-elemenol and β-elemene fluoride had the same antitumor efficacy as β-elemene, whereas β-elemenal was appreciably more potent than β-elemene. Thus, although all three synthetic analogs of β-elemene considerably suppressed NSCLC cell growth and proliferation, β-elemenal may have greater potential as an anticancer alternative to β-elemene in treating lung cancer and other tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23397083     DOI: 10.1007/s12032-013-0488-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  53 in total

Review 1.  The G2-phase DNA-damage checkpoint.

Authors:  M J O'Connell; N C Walworth; A M Carr
Journal:  Trends Cell Biol       Date:  2000-07       Impact factor: 20.808

2.  p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint.

Authors:  V A Smits; R Klompmaker; T Vallenius; G Rijksen; T P Mäkela; R H Medema
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

3.  Breast cancer growth inhibition by delivery of the MDGI-derived peptide P108.

Authors:  H L Wang; A Kurtz
Journal:  Oncogene       Date:  2000-05-11       Impact factor: 9.867

Review 4.  Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience.

Authors:  D H Johnson
Journal:  Chest       Date:  2000-04       Impact factor: 9.410

5.  Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15.

Authors:  P R Mueller; T R Coleman; A Kumagai; W G Dunphy
Journal:  Science       Date:  1995-10-06       Impact factor: 47.728

Review 6.  Cdc2: a monopotent or pluripotent CDK?

Authors:  X Hu; L C Moscinski
Journal:  Cell Prolif       Date:  2011-06       Impact factor: 6.831

7.  A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

Authors:  K Roszkowski; A Pluzanska; M Krzakowski; A P Smith; E Saigi; U Aasebo; A Parisi; N Pham Tran; R Olivares; J Berille
Journal:  Lung Cancer       Date:  2000-03       Impact factor: 5.705

8.  β-elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells.

Authors:  Rebecca X Lee; Qingdi Quentin Li; Eddie Reed
Journal:  Anticancer Res       Date:  2012-08       Impact factor: 2.480

Review 9.  State-of-the-art chemotherapy for advanced non-small cell lung cancer.

Authors:  Sakkaraiappan Ramalingam; Chandra P Belani
Journal:  Semin Oncol       Date:  2004-02       Impact factor: 4.929

10.  Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).

Authors:  C Boni; M Tiseo; L Boni; E Baldini; F Recchia; C Barone; F Grossi; D Germano; E Matano; G Marini; R Labianca; F Di Costanzo; A Bagnulo; C Pennucci; C Caroti; M Mencoboni; F Zanelli; T Prochilo; M A Cafferata; A Ardizzoni
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

View more
  15 in total

1.  Inhibitory effect of β-elemene on human breast cancer cells.

Authors:  Chaying Guan; Weiguo Liu; Yongfang Yue; Hongchuan Jin; Xian Wang; Xiao-Jia Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Screening of critical genes in lung adenocarcinoma via network analysis of gene expression profile.

Authors:  Ping Huang; Kejian Cao; Heng Zhao
Journal:  Pathol Oncol Res       Date:  2014-05-26       Impact factor: 3.201

3.  Exploring new applications of tulip tree (Liriodendron tulipifera L.): leaf essential oil as apoptotic agent for human glioblastoma.

Authors:  Luana Quassinti; Filippo Maggi; Federica Ortolani; Giulio Lupidi; Dezemona Petrelli; Luca A Vitali; Antonino Miano; Massimo Bramucci
Journal:  Environ Sci Pollut Res Int       Date:  2019-08-23       Impact factor: 4.223

Review 4.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 5.  The reversal of antineoplastic drug resistance in cancer cells by β-elemene.

Authors:  Guan-Nan Zhang; Charles R Ashby; Yun-Kai Zhang; Zhe-Sheng Chen; Huiqin Guo
Journal:  Chin J Cancer       Date:  2015-09-14

6.  β-elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKα signalling pathways in human lung cancer cells: the role of Sp1.

Authors:  ShunYu Zhao; Jingjing Wu; Fang Zheng; Qing Tang; LiJun Yang; Liuning Li; WanYin Wu; Swei Sunny Hann
Journal:  J Cell Mol Med       Date:  2015-01-19       Impact factor: 5.310

Review 7.  β-Elemene: Mechanistic Studies on Cancer Cell Interaction and Its Chemosensitization Effect.

Authors:  Ziyu Jiang; Joe A Jacob; Dinesh S Loganathachetti; Prasannabalaji Nainangu; Baoan Chen
Journal:  Front Pharmacol       Date:  2017-03-09       Impact factor: 5.810

8.  An ATF24 peptide-functionalized β-elemene-nanostructured lipid carrier combined with cisplatin for bladder cancer treatment.

Authors:  Bingtao Zhai; Peng Chen; Wengang Wang; Shuiping Liu; Jiao Feng; Ting Duan; Yu Xiang; Ruonan Zhang; Mingming Zhang; Xuemeng Han; Xiaying Chen; Qiujie Li; Guohua Li; Ying Liu; Xingxing Huang; Wenzheng Zhang; Ting Pan; Lili Yan; Ting Jin; Tian Xie; Xinbing Sui
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

9.  β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.

Authors:  Quentin Q Li; Rebecca X Lee; Huasheng Liang; Gangduo Wang; Jueli M Li; Yuhua Zhong; Eddie Reed
Journal:  Int J Oncol       Date:  2013-06-28       Impact factor: 5.650

Review 10.  Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy.

Authors:  Bingtao Zhai; Yiying Zeng; Zhaowu Zeng; Nana Zhang; Chenxi Li; Yijun Zeng; Yu You; Shuling Wang; Xiabin Chen; Xinbing Sui; Tian Xie
Journal:  Int J Nanomedicine       Date:  2018-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.